Compare AstraZeneca plc (AZN) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Lemonade Inc — how do they compare? AstraZeneca plc trades at $158.58 (market cap $248.14B), while Lemonade Inc trades at $51.59 (market cap $4.09B). The key difference: AstraZeneca plc is far larger — about 60.7× Lemonade Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| AZN | LMND | |
|---|---|---|
Market Cap | $248.14B | $4.09B |
Sector | Health | Financials |
52-Week High | $209.48 | $96.57 |
52-Week Low | $147.06 | $47.38 |
Enterprise Value | $275.41B | $3.95B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Lemonade (LMND) trades at $51.21, down 2.79% in the past 24 hours, with a bearish technical signal indicated by moving averages and ADX. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 79% year-over-year, but remains unprofitable with a net income margin of -14.19%. Recent news highlights a CFO transition and expansion into new states, while the stock faces volatility amid mixed analyst sentiment.
The outlook for LMND hinges on achieving profitability, guided for Q4 2026, but high valuation (P/S of 4.1) and persistent losses pose risks. Opportunities include AI-driven growth and market expansion, yet investors face execution risks and competitive pressures in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
